However, the results of clinical trials evaluating those agents as monotherapy were disappointing, as only 3/60 (5%) cases of osteosarcoma treated with the anti-IGF1R mAb robatumumab showed complete or partial response [147]. The gene discussed is IGF1R; the disease is osteosarcoma.